Cover Image
市場調查報告書

肝硬化的開發中產品分析

Cirrhosis - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 192530
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
肝硬化的開發中產品分析 Cirrhosis - Pipeline Review, H2 2014
出版日期: 2014年07月15日 內容資訊: 英文 67 Pages
簡介

所謂肝硬化,是指肝臟部分產生不可逆的疤痕,造成肝臟的異常狀態。主要的原因有持續性過量攝取酒精,及病毒性B型·B型肝炎,脂肪肝病等,但其他仍有許多致病因素。主要的症狀有上腹部皮膚可見到微血管、倦怠感、失眠症、皮膚發癢、食慾不振、體重減少、噁心、肝臟週邊疼痛和壓痛、四肢無力感等。

本報告提供全球各國治療肝硬化用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

肝硬化概要

治療藥的開發

  • 肝硬化開發中產品:概要
  • 肝硬化開發中產品:比較分析

各企業開發中的肝硬化治療藥

大學/研究機關研究中的肝硬化治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 不明確的階段的產品

肝硬化治療藥:開發中的產品一覽(各企業)

肝硬化治療藥:研究中的產品的一覽(大學/研究機關別)

肝硬化治療藥的開發企業

  • Ocera Therapeutics, Inc.
  • Hyperion Therapeutics, Inc.
  • PharmaIN Corporation
  • Alfact Innovation

肝硬化:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ornithine phenylacetate
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • glycerol phenylbutyrate
  • Umbilical Cord Mesenchymal Stem Cell Transplantation
  • ALF-5755
  • PGC Based Natriuretic Peptides

肝硬化治療藥:開發中產品的最新趨勢

肝硬化治療藥:開發暫停的產品

肝硬化治療藥:開發中止的產品

肝硬化相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全7件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5288IDB

Summary

Global Markets Direct's, 'Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Cirrhosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cirrhosis Overview
  • Therapeutics Development
    • Pipeline Products for Cirrhosis - Overview
    • Pipeline Products for Cirrhosis - Comparative Analysis
  • Cirrhosis - Therapeutics under Development by Companies
  • Cirrhosis - Therapeutics under Investigation by Universities/Institutes
  • Cirrhosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cirrhosis - Products under Development by Companies
  • Cirrhosis - Products under Investigation by Universities/Institutes
  • Cirrhosis - Companies Involved in Therapeutics Development
    • Gilead Sciences, Inc.
    • Novartis AG
    • Ocera Therapeutics, Inc.
    • Hyperion Therapeutics, Inc.
    • Intercept Pharmaceuticals, Inc.
    • PharmaIN Corporation
    • Alfact Innovation
  • Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glycerol phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • simtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • erismodegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALF-5755 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGC Based Natriuretic Peptides - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cirrhosis - Recent Pipeline Updates
  • Cirrhosis - Dormant Projects
  • Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting
      • Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan
      • Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
      • May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
      • Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD
      • Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD
      • Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cirrhosis, H2 2014
  • Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014
  • Cirrhosis - Pipeline by Novartis AG, H2 2014
  • Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2014
  • Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H2 2014
  • Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014
  • Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014
  • Cirrhosis - Pipeline by Alfact Innovation, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Cirrhosis - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Cirrhosis, H2 2014
  • Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top